DNTHDianthus Therapeutics, Inc. /DE/
Pharmaceutical Preparations
- Revenue
- $2M
- 67% YoY
- Operating margin
- -8739.3%
- 435% YoY
- EBITDA
- −$178M
- 75% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- —
- AI in 10-K
- —
Red flags 1 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear—Cash flow under 80% of net income
- Dilutive SBCFired11× of revenueOver 10% of revenue
- Payouts exceed cash flowClear0% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear—Over 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | $1M | $6M | $3M | $6M | $2M | 67% |
| Operating income | −$13M | −$30M | −$48M | −$102M | −$178M | 75% |
| Net income | −$13M | −$28M | −$44M | −$85M | −$162M | 91% |
| Operating cash flow | −$10M | −$29M | −$37M | −$78M | −$129M | 65% |
| Capex | $1M | $314K | — | — | — | |
| Stock-based comp | $63K | $2M | $3M | $13M | $23M | 77% |
Deal filings
None.
13D filers
None on file.
Insider trading
- Open-market buys, 12 mo
- $0 · 0
- Open-market sells, 12 mo
- $8M · 11
- Net
- −$8M
Pay vs performance
| Year | CEO total comp | Comp actually paid | TSR (indexed) | Peer TSR |
|---|---|---|---|---|
| FY2025 | — | — | 652 | — |
| FY2024 | — | — | 345 | — |
| FY2023 | — | — | 165 | — |